RT Journal Article
SR Electronic
T1 Performance of a universally offered prenatal screening program incorporating cfDNA in Ontario, Canada: a descriptive population-based cohort study of 280,000 pregnancies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.22.20195123
DO 10.1101/2020.09.22.20195123
A1 Dougan, Shelley D
A1 Okun, Nan
A1 Bellai-Dussault, Kara
A1 Meng, Lynn
A1 Howley, Heather E
A1 Huang, Tianhua
A1 Reszel, Jessica
A1 Lanes, Andrea
A1 Walker, Mark C
A1 Armour, Christine M
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.22.20195123.abstract
AB Objectives To measure the population-based performance and impact of Ontario, Canada’s modified-contingent prenatal screening system for the detection of trisomies 21 (T21) and 18 (T18).Design A retrospective, descriptive cohort study examining routinely collected data from BORN Ontario, which captures linkable population data for prenatal and neonatal health encounters across a variety of settings (e.g., laboratories, birthing hospitals and midwifery practice groups).Setting A province-wide and publicly funded prenatal screening program in Ontario, Canada offering cfDNA screening for those at increased risk of having a pregnancy with T21 or T18.Participants 373,682 singleton pregnancies with an estimated due date between September 1 2016 and March 31, 2019 who were offered publicly funded prenatal screening.Main outcome measures Prenatal detection of T21 or T18, ascertained by cytogenetic results. Performance was assessed by calculating sensitivity, specificity, positive predictive value and negative predictive value against confirmatory diagnostic cytogenetic results and birth outcomes. The secondary objective was to determine the impact of contingent cfDNA screening by measuring uptake and the proportion of T21 screen-positive pregnancies undergoing subsequent cfDNA screening and invasive prenatal diagnostic testing (PND).Results 69% of pregnancies in Ontario underwent prenatal screening for T21/T18. The modified-contingent screen sensitivity was 89.9% for T21 and 80.5% for T18. The modified-contingent screen-positive rate was 1.6% for T21 and 0.2% for T18. The cfDNA screening test failure rate was 2.2% (final result including multiple attempts). The PND rate among pregnancies screened was 2.4%.Conclusions This study is the largest evaluation of population-based performance of a publicly funded cfDNA prenatal screening system. We demonstrated a robust screening system with high sensitivity and low PND consistent with smaller validation studiesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe authors did not receive any funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Research Ethics Boards of Children's Hospital of Eastern Ontario (protocol 19/06PE), Ottawa Health Sciences Network (protocol 20190482-01H), and Mount Sinai Hospital (protocol 19-0181-C).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data set for this study is held securely at the prescribed registry BORN Ontario. Data sharing regulations prevent these data from being made available publicly. Enquiries regarding BORN data may be directed to Science{at}BORNOntario.ca.